CEO of Enhanc3D Genomics. “We have shown, through existing collaborations, that we can improve both timescales and success rates of target identification and drug development using 3D multi-omics." ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the ...

Drug development is a multi-step process where ... better understand how disease variants change cellular function is 3D genomics. Analysis of 3D genomic data provides deep insight into the ...

--(BUSINESS WIRE)--Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable ... of our technologies and accelerating the development of new diagnostic solutions through Arima ...

Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships CAMBRIDGE, England--(BUSINESS ...

3D genomics is particularly useful for cancer research ... immunology and neuroscience will one day enable the development of new diagnostic tools and approaches. Dr. Anthony Schmitt was speaking to ...

The device is able to sequence DNA molecules in 3D tissue samples and at the scale required by spatial genomics. To finance the development of its technology, Single bagged SEK 50 million ($5.9 ...

She has played a leading role in transitioning the Company's 3D genomics platform from development to practical application in R&D. With over a decade of senior leadership experience in oncology ...

Enhanc3D Genomics (‘Enhanced’), an innovator ... through every stage of the drug discovery and development process. Enhanced’s 3D Multi-omic platform is based on patented Promoter Capture ...